
Clean Science Q2 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
No
Order
N/A
Capex
Yes
1 of 4 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- Target to increase HALS sales to 200 tons per month by March FY25, with new products from the series also expected to contribute significantly.
- Non-flagship/new products now contribute 25% of revenues and expected to grow, gradually reducing flagship product revenue share.
- Growth to be driven by volume increases from newer products, including TBHQ and DCC, which are seen as steady, non-cyclical demand products.
- Internal accruals will finance new CAPEX, supported by cash reserves (~Rs. 250 crores).
- Demand recovery expected to be gradual over the next 2-3 quarters, with volumes likely to improve from 2Q FY24 levels.
- Company emphasizes diversification in products and geography which is aiding margin resilience despite volume/realization pressures.
- Pricing likely to remain under pressure until China normalizes; market conditions and pricing trends will be clearer in coming quarters.
See what Clean Science management said on margin guidance — free account, 30 seconds.
Fundraise plans
No- No new fundraising through debt or equity is planned currently.
- All ongoing and planned CAPEX (~Rs. 300 crores through Clean Fino-Chem subsidiary and additional Rs. 170-180 crores for new products) will be fully funded through internal accruals.
- The company has about Rs. 250 crores in cash on the balance sheet to support CAPEX requirements.
- Management emphasized reliance on internal accruals for financing expansions and new projects without the need for external funding.
See what Clean Science management said on order book — free account, 30 seconds.
Capex plans
Yes- Ongoing CAPEX of approximately Rs. 300 crores at Clean Fino-Chem Limited (CFCL), expected to commission by Q4 FY24, fully funded through internal accruals.
- New pilot facility at CFCL to commission within next 4 weeks to aid scale-up from lab to commercial production.
- Additional Rs. 170-180 crores earmarked for new products, announcement expected in next 1-2 quarters.
- Rs. 250 crores investment planned starting January for HALS plant, sales expected to grow thereafter.
- All new CAPEX and expansions to be financed through internal accruals; company currently holds Rs. 250 crores cash.
- Rs. 30 crores CAPEX dedicated to pharma intermediate plant expected to generate Rs. 100 crores revenue, part of overall Rs. 200 crores multiproduct investment block.
- Emphasis on state-of-the-art automated facilities to boost return on assets and reduce time to market.
Track Clean Science — get its next earnings analysis in your feed
How does Clean Science rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Clean Science rank in Chemicals & Petrochemicals?
Compare Clean Science against every Chemicals & Petrochemicals company (Q2 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Clean Science's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Seya Industries (Q2 FY27)
Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's
- DCM Shriram Fine Chemicals (Q2 FY27)
9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri
- Dhariwalcorp (Q2 FY27)
For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…
- Agastya Energy (Q2 FY27)
For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…